<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02409407</url>
  </required_header>
  <id_info>
    <org_study_id>MS20150303</org_study_id>
    <nct_id>NCT02409407</nct_id>
  </id_info>
  <brief_title>Misoprostol Before Hysteroscopy in Infertile Cases</brief_title>
  <official_title>Effectiveness of Oral Versus Vaginal Misoprostol Before Office Hyteroscopy in Infertile Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <brief_summary>
    <textblock>
      The role of hysteroscopy in infertility investigation is to detect possible intrauterine
      changes that could interfere with implantation or growth or both of the conceptus, with the
      invention of miniature hysteroscope, it is possible to perform hysteroscopy in an office
      setting (Outpatient hysteroscopy; OH), for diagnostic and certain therapeutic intervention.
      It is currently acknowledged as the 'gold standard' investigation of the intrauterine
      abnormalities.

      Cervical priming prior to diagnostic hysteroscopy softens the cervix and lessens the force
      needed for dilation, thereby potentially reducing the probability of procedural complication
      such as uterine perforation, cervical laceration, failure to dilate, and creation of a false
      track that can occur during cervical entry.

      Misoprostol is a prostaglandin El analogue, that can be administered either orally or
      vaginally, that can cause cervical ripening by inducing collagenolytic activity and synthesis
      of proteoglycans.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>level of pelvic pain according to a 10-point visual analogue scale (VAS)</measure>
    <time_frame>10 months</time_frame>
    <description>The level of pelvic pain will be rated according to a 10-point visual analogue scale (VAS). The VAS will be applied immediately after the procedure ended</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Oral Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral misoprostol ( prostaglandins E1 analogue) will be administered at a dose of 600 µg (200 µg every 8 hours), starting 24 hours before office hysteroscopy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaginal misoprostol ( prostaglandins E1 analogue)will be administered at a dose of 400 µg (200 µg 12 hours apart, starting 24 hours before office hysteroscopy)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral placebo (one pill every 8 hours) will be administered starting 24 hours before the office hysteroscopy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol , Prostaglandins E1 analogue</intervention_name>
    <arm_group_label>Oral Misoprostol</arm_group_label>
    <arm_group_label>Vaginal Misoprostol</arm_group_label>
    <other_name>Misotac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients aged from 20 to 40 years old.

          -  They are complaining with primary or secondary infertility.

          -  They undergo investigations including husband semen analysis, hormonal assay, U/S,
             Hystrosalpingography.

        Exclusion Criteria:

          -  Known sensitivity to misoprostol.

          -  Any systemic disease contraindicating the use of prostaglandins (cardiovascular
             disease, hypertension, renal failure, etc).

          -  Concomitant neurologic disease that could affect the correct evaluation of pain.

          -  Pregnancy.

          -  Any contraindication to hysteroscopy such as Pelvic inflammatory disease (PID).

          -  Heavy uterine bleeding.

          -  Any uterine abnormality such as pinhole cervix that would obviate passage of a
             catheter through the cervix.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yomna A Bayoumi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kasr El Aini Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yomna A Bayoumi, MD</last_name>
    <phone>01066812955</phone>
    <phone_ext>002</phone_ext>
    <email>dryomnabayoumi@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr el Ainy hospital</name>
      <address>
        <city>Cairo</city>
        <zip>12211</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yomna A Bayoumi, MD</last_name>
      <phone>01066812955</phone>
      <phone_ext>002</phone_ext>
      <email>dryomnabayoumi@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yomna A Bayoumi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 1, 2015</study_first_submitted>
  <study_first_submitted_qc>April 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2015</study_first_posted>
  <last_update_submitted>April 3, 2015</last_update_submitted>
  <last_update_submitted_qc>April 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Yomna Ali Bayoumi</investigator_full_name>
    <investigator_title>Lecturer of Obstetrics and Gynecology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Alprostadil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

